Merrimack Pharmaceuticals Inc., of Cambridge, Mass., said the National Comprehensive Cancer Network included Onivyde (irinotecan liposome injection) in combination with fluorouracil and leucovorin in its 2016 Clinical Practice Guidelines in Oncology for pancreatic adenocarcinoma. Onivyde was approved last year. (See BioWorld Today, Oct. 23, 2015.)